Albanol B is an arylbenzofuran derivative which can be isolated from mulberries. Albanol B exhibits anti-Alzheimer's disease, anti-bacterial and antioxidant activities. Albanol B inhibits cancer cells proliferation, down-regulates CDK1 expression. Albanol B also induces cell cycle arrest at G2/M and apoptosis. And Albanol B induces mitochondrial ROS production and increases the phosphorylation levels of AKT and ERK1/2. In Vitro Albanol B (10 μM, 30 μM; 24 h) decreases cell viability of A549 cells. Albanol B (30 μM; 48 h) arrrests cell cycle at G2/M phase and induces apoptosis in A549 and H1975 cells. Albanol B (1-30 μM; 1-9 h) mediates the activation of ERK-1/2 and AKT in A549 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: A549 cells, BZR, NCI-H1975, and NCI-H226 cells Concentration: 0, 1, 3, 10, and 30 μM Incubation Time: 48 hours Result: Exhibited inhibitory effects on cancer cells with IC 50 s of 5.6 μM (A549), 8.9 μM (BZR), 12.7 μM (NCI-H1975), and 15 μM (NCI-H226), respectively. Cell Cycle AnalysisCell Line: A549 and H1975 cells Concentration: 1, 3, 10 μM Incubation Time: 48 hours Result: Increased cells in G2/M phase from 9.5% to 14.34%, 18.13% and 47.9%, respectively. Western Blot AnalysisCell Line: A549 cells Concentration: 1 h, 3 h, 6 h, and 9 h Incubation Time: 48 hours Result: Increased the phosphorylation levels of ERK1/2 and AKT in time- and concentration-dependent manners. Did not increase the phosphorylation level of JNK and p38 MAPKs. In Vivo Albanol B (50 mg/kg, 100 mg/kg; ip; once daily for 21 days) inhibits tumor growth in Ex-3LL tumor bearing mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: EX-3LL tumor-bearing mice Dosage: 50 mg/kg, 100 mg/kg Administration: IP; once daily for 21 days Result: Decreased tumor volume and weight by 48.0% and 41.0% (for 50 mg/kg treatment), and 61.3% and 57.3% (for 100 mg/kg treatment), respectively.